Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1027-1031

  Wang, Hengbing ^a   Cao, Qing ^b   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bortezomib; Gemcitabine; Histone deacetylation; Pancreatic cancer; Panobinostat; Proteasome inhibition

Indexed keywords

BORTEZOMIB; GEMCITABINE; PANOBINOSTAT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CHEMISTRY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; HEART FUNCTION; HUMAN; HYPOKALEMIA; INTERNATIONAL NORMALIZED RATIO; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID FUNCTION TEST; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PYRAZINES;

EID: 84863339591     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Saif MW: Pancreatic neoplasm in 2011: an update. JOP 12(4): 316-321, 2011.
2. Conroy T, Gavoille C and Adenis A: Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 23(4): 390-395, 2011.
3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11): 2615-2622, 1999. (Pubitemid 29269108)
4. Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5(9): 2638-2645, 1999. (Pubitemid 29437352)
5. Cusack JC Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61(9): 3535-3540, 2001. (Pubitemid 32694955)
6. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr. and Eder JP: Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 107(10): 2482-2489, 2006. (Pubitemid 44748533)
7. Yu C, Rahmani M Conrad D, Subler M, Dent P and Grant S: The proteasome inhibitor botezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to ST5171. Blood 102(10): 3765, 2003.
8. Heider U, von Metzler, I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM and Sezer O: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor botezomib in mantle cell lymphoma. Eur J Haematol 80(2): 133-142, 2008.
9. Denlinger CE, Rundal BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation or reactive oxygen species. J Thorac Cardiovasc Surg 128(5): 740-748, 2004. (Pubitemid 39388930)
10. Bai J, Demirjian A, Sui J, Marasco W and Callery MP: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348(4): 1245-1253, 2006. (Pubitemid 44291339)
11. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL and McConkey DJ: Aggresome Disruption: A Novel Strategy to Enhance Botezomib-Induced Apoptosis in Pancreatic Cancer Cells. Cancer Res 66(7): 3773-3781, 2006.
12. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001. (Pubitemid 33741894)
13. Glozak MA, Sengupta N, Zhang X and Seto E: Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23, 2005. (Pubitemid 41691888)
14. Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (review). Int J Oncol 33: 637-646, 2008.
15. Aoyagi S and Archer T: Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15(11): 565-567, 2005. (Pubitemid 41619418)
16. Diaz-Gonzalez JA, Russell J, Rouzant A, Gil-Bazo I and Montuenga L: Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 4(10): 1055-1062, 2005. (Pubitemid 41598557)
17. Zhou Q, Agoston AT, Atadja P, Nelson WG and Davidson NE: Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells. Mol Cancer Res 6(5): 873-883, 2008.
18. Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous t-cell lymphoma. Oncologist 12(10): 1247-1252, 2007. (Pubitemid 350106355)
19. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J and Ando Y: Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs. 2011 Oct 1. [Epub ahead of print]
20. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV and Burris HA: A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 29(7): 451-455, 2011.
21. San-Miguel JF, Richardson PGG, Sezer O, Guenther A, Siegel DSD, Blade J, LeBlanc R, Sutherland HJ, Mateos M, Gramatzki M, Hazell KM, Bengoudifa B, Bourquelot PM and Anderson KC: A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 29: (suppl; abstr 8075), 2011.
22. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(7): 13-47, 2000. (Pubitemid 30179675)
23. MSSO official Web page: http://www.meddramsso.com.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.
25. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H and Oettle H: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47(11): 1676-1681, 2011.
26. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM and Duvic M: Phase Hb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21): 3109-3115, 2007. (Pubitemid 47218059)
27. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS and Chuang DM: Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321(3): 892-901, 2007. (Pubitemid 46762687)
28. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M and Bhalla K: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15): 4628-4635, 2006. (Pubitemid 44297814)
29. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K and Yamamoto N: A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 2011 Apr 12. [Epub ahead of print]